At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
VIR-2218 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
In Brief
A Phase 2 clinical trial evaluating VIR-2218 and Placebo for Hepatitis B, Chronic. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesChina
CollaboratorsVir Biotechnology, Inc., Alnylam Pharmaceuticals
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionSep 2021
TodayJul 2026
First PostedAug 11, 2020
Enrollment StartAug 18, 2020
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
VIR-2218drug
VIR-2218 given by subcutaneous injection
Placebodrug
Saline given by subcutaneous injection